PDL Biopharma

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and providing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used for the treatment of hypertension. Noden Pharma aims to enhance the lives of patients by offering effective medical solutions in international markets.

Kaleo, Inc. is a specialty pharmaceutical company based in Richmond, Virginia, that develops, markets, and sells innovative drug and medical products. Founded in 2008, the company specializes in creating combination drug/device products designed to empower patients in managing their health conditions. Its notable offerings include AUVI-Q, an epinephrine auto-injector for treating severe allergic reactions in infants and small children, and EVZIO, a naloxone injection for opioid overdose. Kaleo's product development emphasizes patient-centric approaches and leverages advanced drug delivery technology to enhance treatment efficacy and safety. The company provides its products through distributors in the United States and Canada and is committed to delivering solutions that improve clinical and economic outcomes for patients and healthcare providers.

Paradigm Spine, LLC is a privately-held medical device company based in New York, specializing in the design, development, and marketing of innovative solutions for spinal diseases. The company focuses on non-fusion spinal implant technology, offering a range of minimally invasive products aimed at treating conditions such as lumbar spinal stenosis and age-related spinal deformities. Key offerings include the Coflex interspinous implant, which is used for facet arthrosis and decompression procedures, as well as the DSS system, a minimally-invasive pedicle-screw based solution. Paradigm Spine emphasizes the development of surgeon-centric and indication-specific products that preserve motion and support natural anatomical function, catering to spine specialists worldwide. Founded in 2002, the company was previously known as Spine Motion, LLC before rebranding in 2005.

Direct Flow Medical is a medical device company focused on developing innovative transcatheter aortic valve replacement systems aimed at treating cardiac valve insufficiency. The company’s flagship product is a percutaneous aortic tissue valve prosthesis designed to offer a safe and effective alternative for patients, particularly those over the age of 65 who suffer from calcified aortic valves. Despite the prevalence of this condition, with approximately 1.2 million affected individuals, only around 150,000 receive surgical treatment annually. Direct Flow Medical's technology enhances patient outcomes and minimizes complications by allowing heart surgeons to perform valve replacements without invasive surgery, using repeated assessments of hemodynamic performance prior to final implantation.

Durata Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments for infectious diseases and acute illnesses. The company's primary focus is on Dalvance, an intravenous antibiotic designed to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria in adults. In addition to Dalvance, Durata is advancing two preclinical antibiotic programs, showcasing its commitment to addressing critical healthcare needs in the field of infectious diseases. The company was established through a collaboration of several venture capital firms to facilitate the late-stage clinical development of its antibiotic candidates.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

AxoGen, Inc. is a company focused on developing and commercializing innovative solutions for the repair and regeneration of peripheral nerve injuries. Based in Alachua, Florida, and founded in 2002, AxoGen offers a range of products designed for effective surgical procedures, including the AVANCE Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. Additionally, it provides the Axotouch Two-Point Discriminator, a device used to assess the innervation density of skin. AxoGen's offerings are aimed at surgeons and healthcare providers, ensuring clinically and economically effective solutions for nerve repair. The company also has a strategic partnership with the American Tissue Services Foundation for tissue recovery and distributes its products across the United States and several international markets, including Canada, Germany, the United Kingdom, Spain, and South Korea.

ESP Pharma is a hospital-focused pharmaceutical company that specializes in acquiring and enhancing the marketing of approved specialty therapeutics and late-stage development drugs. The company is dedicated to providing effective therapeutics to physicians, hospitals, and acute-care patients, particularly in the areas of high blood pressure and angina. Additionally, ESP Pharma develops specialty pharmaceutical products aimed at improving the quality of care for patients undergoing treatments such as bone marrow transplants. By concentrating on the acute-care setting, ESP Pharma seeks to enable better healthcare outcomes for patients.